% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ko:274366,
      author       = {A. H. Ko and K.-P. Kim and J. Siveke$^*$ and C. D. Lopez
                      and J. Lacy and E. M. O'Reilly and T. Macarulla and G. A.
                      Manji and J. Lee and J. Ajani and M. Alsina Maqueda and
                      S.-Y. Rha and J. Lau and N. Al-Sakaff and S. Allen and D. Lu
                      and C. S. Shemesh and X. Gan and E. Cha and D.-Y. Oh},
      title        = {{A}tezolizumab {P}lus {PEGPH}20 {V}ersus {C}hemotherapy in
                      {A}dvanced {P}ancreatic {D}uctal {A}denocarcinoma and
                      {G}astric {C}ancer: {MORPHEUS} {P}hase {I}b/{II} {U}mbrella
                      {R}andomized {S}tudy {P}latform.},
      journal      = {The oncologist},
      volume       = {28},
      number       = {6},
      issn         = {1083-7159},
      address      = {Oxford},
      publisher    = {Oxford University Press},
      reportid     = {DKFZ-2023-00568},
      pages        = {553-e472},
      year         = {2023},
      note         = {2023 Jun 2;28(6):553-e472},
      abstract     = {The MORPHEUS platform comprises multiple open-label,
                      randomized, phase Ib/II trials designed to identify early
                      efficacy and safety signals of treatment combinations across
                      cancers. Atezolizumab (anti-programmed cell death 1 ligand 1
                      [PD-L1]) was evaluated in combination with PEGylated
                      recombinant human hyaluronidase (PEGPH20).In 2 randomized
                      MORPHEUS trials, eligible patients with advanced, previously
                      treated pancreatic ductal adenocarcinoma (PDAC) or gastric
                      cancer (GC) received atezolizumab plus PEGPH20, or control
                      treatment (mFOLFOX6 or gemcitabine plus nab-paclitaxel
                      [MORPHEUS-PDAC]; ramucirumab plus paclitaxel [MORPHEUS-GC]).
                      Primary endpoints were objective response rates (ORR) per
                      RECIST 1.1 and safety.In MORPHEUS-PDAC, ORRs with
                      atezolizumab plus PEGPH20 (n = 66) were $6.1\%$ $(95\%$ CI,
                      $1.68\%-14.80\%)$ vs. $2.4\%$ $(95\%$ CI, $0.06\%-12.57\%)$
                      with chemotherapy (n = 42). In the respective arms, $65.2\%$
                      and $61.9\%$ had grade 3/4 adverse events (AEs); $4.5\%$ and
                      $2.4\%$ had grade 5 AEs. In MORPHEUS-GC, confirmed ORRs with
                      atezolizumab plus PEGPH20 (n = 13) were $0\%$ $(95\%$ CI,
                      $0\%-24.7\%)$ vs. $16.7\%$ $(95\%$ CI, $2.1\%-48.4\%)$ with
                      control (n = 12). Grade 3/4 AEs occurred in $30.8\%$ and
                      $75.0\%$ of patients, respectively; no grade 5 AEs
                      occurred.Atezolizumab plus PEGPH20 showed limited clinical
                      activity in patients with PDAC and none in patients with GC.
                      The safety of atezolizumab plus PEGPH20 was consistent with
                      each agent's known safety profile. (ClinicalTrials.gov
                      Identifier: NCT03193190 and NCT03281369).},
      keywords     = {PD-L1 (Other) / basket study (Other) / combination therapy
                      (Other) / gastric cancer (Other) / hyaluronan (Other) /
                      immunotherapy (Other) / pancreatic cancer (Other) / proof of
                      concept (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36940261},
      doi          = {10.1093/oncolo/oyad022},
      url          = {https://inrepo02.dkfz.de/record/274366},
}